2m 2m 2m 2m 2m 2m 2m
Rein Therap (RNTX)
NASDAQ
$1.03+$0.01 (+0.98%)
Price as of Jun 03, 2026 7:02 PM EDT- $94.9MMarket Cap
- -49.01%1-Year Change
- BiotechnologyIndustry
Rein Therap (RNTX)
$1.03+$0.01 (+0.98%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Cost of Revenue | 35,000 0.00% | 35,000 -68.18% | 110,000 0.00% | 110,000 -24.14% | |
Gross Profit | -35,000 0.00% | -35,000 -68.18% | -110,000 0.00% | -110,000 -24.14% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -11.0M -22.59% | -14.2M +257.00% | -4.0M -77.79% | -18.0M +5.64% | |
Depreciation and Amortization Expense | 1,000 -98.41% | 63,000 -47.06% | 119,000 -29.59% | 169,000 +39.67% | |
Total Operating Expenses | 50.6M -22.24% | 65.1M +300.05% | 16.3M -41.13% | 27.6M +3.92% | |
Operating Profit | -50.6M -22.24% | -65.1M +300.05% | -16.3M -41.13% | -27.6M +3.92% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 48,000 -92.99% | 685,000 +25.92% | 544,000 +71.07% | 318,000 -27.89% | |
Income before Taxes | -50.6M -22.24% | -65.1M +300.05% | -16.3M -41.13% | -27.6M +3.92% | |
Income Taxes | -712,000 -53.89% | -1.5M N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -49.9M -20.69% | -62.9M +299.71% | -15.7M -42.43% | -27.3M +4.45% | |
Net Income from Continuing Operations Applicable to Common | -49.9M -20.69% | -62.9M +299.71% | -15.7M -42.43% | -27.3M +4.45% | |
Basic EPS and Net Income | -1.96 -44.16% | -3.51 +2.63% | -3.42 -43.19% | -6.02 +1,975.86% | |
Diluted EPS and Net Income | -1.96 -44.16% | -3.51 +2.63% | -3.42 -43.19% | -6.02 +1,975.86% | |
Basic Weighted Average Shares | 25.4M +41.84% | 17.9M +290.09% | 4.6M +1.31% | 4.5M -94.89% | |
Diluted Weighted Average Shares | 25.4M +41.84% | 17.9M +290.09% | 4.6M +1.31% | 4.5M -94.89% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 3.2M -75.01% | 12.9M -25.69% | 17.3M +233.33% | 5.2M +44.28% | |
Short-Term Investments | N/A N/A | N/A N/A | 16.0M 0.00% | 16.0M -62.09% | |
Cash and Cash Equivalents and Short-Term Investments | 3.2M -75.01% | 12.9M -61.44% | 33.4M +57.05% | 21.2M -53.75% | |
Total Current Assets | 4.3M -68.32% | 13.7M -25.23% | 18.3M -16.49% | 21.9M -54.60% | |
Accumulated Depreciation | N/A N/A | N/A N/A | 358,000 +32.59% | 270,000 +27.36% | |
Property and Plant and Equipment and Net | 0 -100.00% | 1,000 -94.74% | 19,000 -72.86% | 70,000 -45.31% | |
Total Long-Term Assets | 2,000 0.00% | 2,000 -99.91% | 2.2M +9,037.50% | 24,000 0.00% | |
Total Assets | 24.2M -61.15% | 62.2M -41.33% | 106.0M +381.70% | 22.0M -54.61% | |
Income Taxes Payable | 1.1M -40.18% | 1.8M -46.72% | 3.3M N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 6.2M +7.50% | 5.7M +31.11% | 4.4M +29.58% | 3.4M -24.93% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 0 -100.00% | 277,000 -95.84% | 6.7M +9,540.58% | 69,000 0.00% | |
Total Liabilities | 7.2M -7.16% | 7.8M +1.13% | 7.7M +127.87% | 3.4M -26.07% | |
Retained Earnings | -401.3M +14.19% | -351.4M +21.80% | -288.5M +5.77% | -272.8M +11.13% | |
Total Stockholders Equity | 45.0M 0.00% | 45.0M +553.48% | 6.9M -63.02% | 18.6M -57.58% | |
Total Shares Outstanding | 27.6M +27.16% | 21.7M +343.47% | 4.9M +7.58% | 4.5M -94.99% | |
Cash Flow | |||||
Cash from Operating Activities | -19.4M -13.14% | -22.3M +12.54% | -19.8M -20.34% | -24.9M +4.68% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | 157,000 0.00% | |
Cash from Investing Activities | N/A N/A | 0 -100.00% | 16.2M -38.79% | 26.5M +173.67% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 9.8M -45.25% | 17.8M +12.81% | 15.8M -71.62% | 55.7M 0.00% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -115.51% +54.48% | -74.77% +204.22% | -24.58% -68.30% | -77.54% -3.94% | |
Return on Equity | -110.81% -54.28% | -242.36% +96.50% | -123.34% +41.10% | -87.41% -6.34% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 0.70 -70.53% | 2.38 -42.97% | 4.17 -35.55% | 6.46 -39.52% | |
Cash Ratio | 0.52 -76.75% | 2.24 -43.32% | 3.95 +157.23% | 1.53 +92.20% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow